Durable Clinical and Pathologic Response of Hepatocellular Carcinoma to Systemic and Hepatic Arterial Administration of Platinol, Recombinant Interferon α 2B, Doxorubicin, and 5-Fluorouracil
- 1 April 1999
- journal article
- case report
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 22 (2) , 209-213
- https://doi.org/10.1097/00000421-199904000-00024
Abstract
The case described here illustrates the antitumor activity of a four-drug systemic combination chemobiotherapy with platinol, recombinant interferon alpha 2b, doxorubicin (Adriamycin), and 5-fluorouracil (5-FU) (PIAF) in a patient with diffuse hepatocellular carcinoma involving the liver and lungs.Keywords
This publication has 25 references indexed in Scilit:
- Recombinant interferon-α in inoperable hepatocellular carcinoma: A randomized controlled trialHepatology, 1993
- A Phase 2 Study of Cisplatin in Patients with Hepatocellular CarcinomaOncology, 1993
- Recombinant α2 interferon is superior to doxorubicin for inoperable hepatocellular carcinoma: a prospective randomised trialBritish Journal of Cancer, 1989
- Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trialCancer, 1988
- Adriamycin treatment for hepatocellular carcinoma experience with 109 patientsCancer, 1985
- Induction of remission in hepatocellular carcinoma: A comparison of VP 16 with adriamycinCancer, 1983
- Chemotherapy studies in primary liver cancer. A prospective randomized clinical trialCancer, 1978
- A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United StatesCancer, 1977
- Adenocarcinomas of stomach, pancreas, liver, and biliary tracts.Survival of 328 patients treated with fluoropyrimidine therapyCancer, 1974
- Comparison of treatment of metastatic gastrointestinal cancer with 5-fluorouracil (5-FU) to a combination of 5-FU with cytosine arabinosideCancer, 1972